Table 6.
Multivariate Cox regression analysis of associations of baseline eGFR with the mortality in patients with COVID-19.
| Variable | Unadjusted HR (95% CI) | p value | Adjusted HR (95% CI) a | p value |
|---|---|---|---|---|
| All patients | ||||
| eGFR, ml/min/1.73 m2 | ||||
| ≥ 90 | 1.0 (Ref) | 1.0 (Ref) | ||
| 60–89 | 3.399 (1.961–5.892) | 0.000 | 3.723 (1.565–8.854) | 0.003 |
| < 60 | 11.155 (6.504–19.135) | 0.000 | 7.382 (3.026–18.011) | 0.000 |
| Patients aged 18–64 | ||||
| eGFR, ml/min/1.73 m2 | ||||
| ≥ 90 | 1.0 (Ref) | 1.0 (Ref) | ||
| 60–89 | 0.992 (0.125–7.908) | 0.000 | 1.459 (0.174–12.219) | 0. 728 |
| < 60 | 11.168 (3.377–36.933) | 0.000 | 11.064 (3.055–40.065) | 0.000 |
| Patients aged ≥ 65 | ||||
| eGFR, ml/min/1.73 m2 | ||||
| ≥ 90 | 1.0 (Ref) | 1.0 (Ref) | ||
| 60–89 | 2.300 (1.240–4.266) | 0.008 | 3.393 (1.184–21.960) | 0.023 |
| < 60 | 7.284 (3.897–13.617) | 0.000 | 7.430 (2.514–9.725) | 0.010 |
aadjusted for disease severity, hypertension, diabetes, coronary artery heart disease, cerebrovascular disease, leukocyte count, lymphocyte count, CRP, IL-6, and procalcitonin.
COVID-19, coronavirus disease 2019; eGFR, estimated glomerular filtration rate; HR, hazard ratio; CI, confidence interval.